AF detected on implanted cardiac implantable electronic devices: Is there a threshold for thromboembolic risk? topical collection on arrhythmia

被引:1
作者
Baibars M. [1 ]
Kanjwal K. [2 ]
Marine J.E. [2 ]
机构
[1] Hospital Medicine, Internal Medicine Department, Peninsula Regional Medical Center, Salisbury, MD
[2] Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, 600 North Wolfe Street
关键词
Atrial fibrillation; Atrial high rate; Implantable cardioverter defibrillator; Insertable loop recorder; Pacemaker; Stroke; Thromboembolism;
D O I
10.1007/s11936-013-0289-7
中图分类号
学科分类号
摘要
Atrial fibrillation (AF) is a common cardiac arrhythmia that is associated with elevated thromboembolism risk caused by multiple pathophysiologies, including a hypercoagulable state, structural heart changes, left atrial appendage stasis, inflammation, and endothelial dysfunction. With the exception of lone AF, most other categories of AF, whether paroxysmal or persistent, have been shown to share a high thromboembolism risk. Risk stratification schemes such as CHADS2 and CHA2DS2-VASc scores help to identify the level at which anticoagulation may mitigate thromboembolism risk. AF may be episodic and asymptomatic; therefore, AF diagnosis that depends entirely on office electrocardiogram (ECG) may be easily missed. With the increasing use of pacemakers, implantable cardioverter defibrillators (ICDs), and insertable loop recorders (ILRs) for diagnosis and treatment of arrhythmias, AF has been incidentally detected with increasing frequency. However, the sensitivity and specificity for detection of AF, especially brief episodes, vary from one type of device to another, and rhythm confirmation should be considered. Several recent studies have examined device-detected AF and have tried to follow associated clinical outcomes. In this paper, we review studies that have addressed device-detected AF and associated thromboembolism risk to try to identify the burden of AF that is associated with an elevated risk of thromboembolism and may therefore warrant anticoagulation therapy.
引用
收藏
相关论文
共 91 条
[21]  
Final results, Circulation, 84, 2, pp. 527-539, (1991)
[22]  
Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study, Lancet, 343, 8899, pp. 687-691, (1994)
[23]  
Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study, JAMA: J Am Med Assoc, 279, 16, pp. 1273-1277, (1998)
[24]  
Wyse D.G., Waldo A.L., Dimarco J.P., Domanski M.J., Rosenberg Y., Schron E.B., Et al., A comparison of rate control and rhythm control in patients with atrial fibrillation, N Engl J Med, 347, 23, pp. 1825-1833, (2002)
[25]  
Van Gelder I.C., Hagens V.E., Bosker H.A., Kingma J.H., Kamp O., Kingma T., Et al., A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation, N Engl J Med, 347, 23, pp. 1834-1840, (2002)
[26]  
Carlsson J., Miketic S., Windeler J., Cuneo A., Haun S., Micus S., Et al., Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study, J Am Coll Cardiol, 41, 10, pp. 1690-1696, (2003)
[27]  
Opolski G., Torbicki A., Kosior D.A., Szulc M., Wozakowska-Kaplon B., Kolodziej P., Et al., Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study, Chest, 126, 2, pp. 476-486, (2004)
[28]  
Hagens V.E., Ranchor A.V., Van Sonderen E., Bosker H.A., Kamp O., Tijssen J.G., Et al., Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study, J Am Coll Cardiol, 43, 2, pp. 241-247, (2004)
[29]  
Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., Et al., Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study, JAMA: J Am Med Assoc, 285, 18, pp. 2370-2375, (2001)
[30]  
Sparks P.B., Mond H.G., Kalman J.M., Jayaprakash S., Lewis M.A., Grigg L.E., Atrial fibrillation and anticoagulation in patients with permanent pacemakers: Implications for stroke prevention, Pacing Clin Electrophysiol: PACE, 21, 6, pp. 1258-1267, (1998)